The cell-surface receptor for advanced glycation end-products (RAGE) has been implicated in the development of diabetic vascular complications and Alzheimer's disease. RAGE has been considered to be involved in amyloid- 1-42 (A 1-42 ) uptake into brain. In the present study, we demonstrate that endogenous secretory RAGE (esRAGE), a decoy form of RAGE generated by alternative RNA processing, is able to inhibit 
Introduction
Receptor for advanced glycation end-products (RAGE) is a pattern recognition receptor, which binds to not only advanced glycation end-products (AGE) [1] , but also S100/calgranulins [2] , Mac-1 [3] , transthyretin [4] , high mobility group box-1 (HMGB-1)/amphoterin [5] , lipopolysaccharides (LPS) [6] , phosphatidylserine [7] , and amyloid- (A) [8] . Interactions of these diverse ligands with RAGE contribute to various pathologic processes including diabetic complications [9, 10] , proinflammatory reactions, tumor progression, efferocytosis, and Alzheimer's disease (AD) [11, 12] .
The presence of senile plaque formed by extracellular amyloid depositions and that of intracellular neurofibrillary tangles composed of hyperphosphorylated tau proteins are the major pathological hallmarks of AD [13] . The predominant forms of non-fibrillar A that give rise to amyloid plaques are A and A fragments [14] .
While soluble A is the major form of circulating A and cerebrovascular amyloid, the major constituent of amyloid plaques is A . A rapidly forms oligomers at very low concentrations, and thus has been regarded as the major cause of neurotoxicity at an early stage of AD [15] . Monomeric A is reported to have neuroprotective effects against A -induced neuronal damage [16, 17] .
Transport of peptides at the blood-brain barrier (BBB) requires a receptor-or carrier-mediated transport system [18] . Unrestricted diffusion readily occurs across the capillaries in peripheral organs, such as the heart, but not across the BBB [19] . Studies using an in vitro model of BBB showed that RAGE mediated the binding of soluble A at the apical side of brain capillary endothelium, and that RAGE was involved in A 1-40 transcytosis [20] . Low-density lipoprotein receptor-related protein-1 (LRP-1) is also known to participate in the receptor-mediated flux of Aacross BBB [21, 22] .
LRP-1 appears to mediate the efflux of A from the brain to the periphery, whereas RAGE is implicated in A influx back into the CNS [22] . Deletion of the RAGE gene eliminates the transport of free circulating A into the brain [23] . Giri et al. reported that RAGE is also involved in A 1-40 -mediated migration of monocytes across BBB [24] .
RAGE has multiple isoforms both in human and mouse. Membrane-bound RAGE transduces intracellular signaling upon ligand engagement on the cell surface. Soluble forms of RAGE act as decoy receptors in the extracellular space [25] [26] [27] [28] [29] . Soluble forms of RAGE can be generated by the following two mechanisms; one is alternative splicing of RAGE transcripts [25] , and the other is ectodomain shedding [26] [27] [28] [29] . We isolated the former variant which is stably present in human blood and named it endogenous secretory RAGE (esRAGE). esRAGE is capable of capturing ligands, thereby protecting cells from ligand-induced injury [25] . Immunohistochemical analysis with RAGE domain-specific antibodies revealed that expression of esRAGE could be higher than that of membrane-bound RAGE in human brain [30] . We also showed lower expression of esRAGE in hippocampal CA1 region of AD brain than that of non-AD brain [31] .
These observations have prompted us to determine whether a higher concentration of circulating esRAGE could exert a protective effect against AD. In the present study, we first confirmed human A  -esRAGE interaction, then created human esRAGE-overexpressing transgenic (Tg) mice, and compared 125 I-labeled A influx into the brain among wild-type (WT), esRAGE Tg and RAGE-null mice.
Materials and Methods

Chemicals
Human A Human esRAGE-specific antibody used for western blot analysis of sera and for ELISA was immunoaffinity-purified rabbit anti-human esRAGE-specific polyclonal antibody raised against the unique C-terminal 16-amino-acid peptide (amino acids 332-347; EGFDKVREAEDSPQHM) [25] . This antibody recognizes human but not mouse esRAGE. Pan-RAGE antibody for western blot analysis of brain was goat anti-RAGE antibody raised against synthetic peptide that corresponds to amino acids 42-59 of human RAGE (Millipore). This antibody recognizes both membrane-bound RAGE and esRAGE of either human or mouse origin.
Animals
Human esRAGE Tg mice were created as follows. A 1,044-bp fragment of human esRAGE cDNA, mouse albumin enhancer/promoter (National Cancer Institute, USA) [32] , human -globin intron, and SV40 late poly(A) region were used for the construction of a transgene ( Fig. 2A) . The transgene was injected into fertilized BDF1 ova for production of the Tg mice (Japan SLC, Inc.). Germline transmitted Tg mice were then backcrossed into C57BL6/J (>7 generations), and the heterozygous Tg mice
were used in the current study. Genotyping was carried out by PCR analysis with the following primers corresponding to the region of the albumin enhancer/promoter:
forward, 5'-GCTTGGCTTGAACTCGTT-3' and reverse, 5'-GCTACCTTAAAGATCCCG-3'. The transgene-carrying allele yielded a band at 404 bp on agarose gel electrophoresis.
The esRAGE Tg mice, RAGE-null mice developed in our lab [33] , and WT C57BL/6J mice (Charles River, Yokohama, Kanagawa, Japan) were housed in a pathogen-free barrier facility and maintained on normal rodent chow with free access to food and water. has been successfully applied to other RAGE ligands, including AGE themselves [33] .
Western blot analysis
Extraction of RAGE proteins from brain in esRAGE Tg, RAGE-null, and WT mice were performed as previously described [34] . One l each of sera from esRAGE Tg, RAGE-null, and WT mice or 10 l each of affinity-purified brain extracts from esRAGE Tg, RAGE-null, and WT mice were loaded. Proteins were separated by SDS-PAGE (12.5%) and electroblotted onto PVDF membranes (Millipore). The membranes were blocked with 5% (w/v) non-fat dried milk in PBS and 0.1% (v/v) Tween 20, and then incubated with 0.5 g/mL of rabbit anti-human esRAGE-specific polyclonal antibody [25] or 1,000-fold diluted goat pan-RAGE antibody (Millipore).
Anti-Rabbit IRDye 680 and 800 were diluted 10,000-fold and used as the secondary antibody. The antigen-antibody complex was visualized using the Odyssey Infrared
Imaging systems (LI-COR Biotechnology, Linclon, Nebraska, USA). Quantification of the intensity of immunoreacted bands was performed with the public domain Image J program in the 256-grayscale mode.
ELISA
ELISA kit (B-Bridge International, Inc) was employed to determine serum levels of human esRAGE in esRAGE Tg, RAGE-null and WT mice as described previously [35] . The ELISA system is not interfered by an addition of ligands.
Radioiodination of A 1-42
Human A 1-42 peptides were labeled with 125 I by the method of chloramine-T as described previously [36] [37] [38] . Labeling and HPLC purification were carried out at The reaction mixture (total: 165 L) was applied onto a Zorbax 300 Extend-C18 (4.6 mm inner diameter x150 mm length) column equilibrated with TBS (pH 7.4) at a 1 ml/min flow rate at 45°C, and separated with the 125 I radioactivity and the absorbance at 220 nm being constantly monitored. The eluates were fractionated into glass tubes (2~4 mL/tube). Fractions containing labeled A were collected and further separated in the same column but using a 20-60% linear gradient of acetonitrile in 0.1% TFA and a flow rate of 1 ml/min. After the chromatography, the solvent in the glass tube was evaporated under nitrogen gas. The recovery of the radioactivity was 91.3%. Purity of the radiolabeled peptides was evaluated by paper chromatography. The ratio of the radioactivity incorporated into amyloid peptides/the radioactivity loaded on the paper chromatography was 2,697.90 x 10 3 cpm/2,733.99 x 10 3 cpm = 98.7%. When the ratio was greater than 95%, the radiolabeled material was considered pure enough to be used for biological analyses; the purified peptides were initially dissolved in DMSO, diluted to a concentration of 1 mg/mL in TBS, and analyzed for degree of oligomerization by SDS-PAGE. The final radioactivity associated with 125 I-labeled A 1-42 was estimated to be 224 Ci/300 L. 
In vivo autoradiography
A hundred Ci of 125 I-labelled A 1-42 tracer (4.6 M as A 1-42 concentration) was injected into the tail vein. At 30 min after the injection, animals were euthanized and blood vessels were immediately perfused. Then, the brain was quickly removed, fixed using Tissue-Tek (Sakura Finetek Japan Co., Ltd., Tokyo, Japan) and kept frozen in powdered dry ice. Serial coronal sections containing the hippocampus or cerebellum were exposed to tritium-imaging plate for 1 week. To quantitatively evaluate the autoradiograms, photo-stimulated luminescence (PSL) values were assessed using the Bio-Imaging Analyzer System (Fuji Film, Hamamatsu, Japan). Regions of interest (ROIs) on the slices included the cerebral cortex, hippocampus, striatum, thalamus, and cerebellum. The signal intensities in these regions are expressed as background-subtracted photo-stimulated luminescence values per square millimeter.
Statistical analysis
Statistical analysis was performed using ANOVA with StatView software. p<0.05
was considered significant.
Results
Physical binding of A 1-42 to esRAGE
We first examined direct physical binding of human A to human esRAGE by SPR. Purified esRAGE protein bound in a concentration-dependent manner to human A immobilized onto a BIAcore sensor chip (Fig. 1A) . The association rate constant (ka), dissociation rate constant (kd) and the equilibrium dissociation constant (Kd) of esRAGE binding to human A (Fig. 1D) . The binding between two was almost completely inhibited by more than 100 g/mL of esRAGE in this assay condition.
Creation of transgenic mice with high level of human esRAGE in circulation
We attempted to create an animal model, in which high serum concentration of human esRAGE protein is achieved, in order to test the protective potential of this variant against AD. For this, we employed the cDNA coding for human esRAGE and the murine albumin enhancer/promoter, which was expected to drive an abundant production of esRAGE proteins and to liberate them into circulation. Fig. 2A shows a schematic representation of the transgene construct. Heterogenous esRAGE Tg mice develop normally and are fertile; body weight of the esRAGE Tg was not different from that of WT for the observation period of experimentation as was the case for RAGE-null mice (data not shown). Serum from esRAGE Tg clearly gave, but WT or RAGE-null mice-derived serum did not, the band immunoreacted with anti-human esRAGE protein antibody at 50 kDa, to which human esRAGE proteins migrated (Fig. 2B) . When sera were assayed with the human esRAGE ELISA system, the mean esRAGE concentration was estimated to be 2.39 ± 0.19 g/mL in esRAGE Tg (n= 67) (Fig. 2C ). This value was more than 4 orders of magnitude higher than the mean in normal human subjects (0.13 ± 0.06 ng/mL) [35] . Human esRAGE protein was not detected either in WT or RAGE-null mice (Fig. 2C) . Next we determined the levels of endogenous membrane-bound RAGE protein and transgene-derived human esRAGE in brain from WT, RAGE-null and esRAGE Tg mice using pan-RAGE antibody with which both membrane-bound RAGE and esRAGE of either human or mouse origin can be simultaneously evaluated. As shown in Fig. 2D , the membrane-bound RAGE was expressed to a similar extent in brain of WT and esRAGE Tg mice. On the other hand, human esRAGE was detected only in esRAGE Tg mice. RAGE immunoreactivity was not detected in RAGE-null mice. The results thus indicate that the murine albumin promoter-human esRAGE transgene did direct the synthesis of large amounts of circulating esRAGE.
Characterization of radiolabeled A 1-42
Fig . 3A shows the elution profile of 125 I-labeled A in reverse-phase HPLC.
When eluted with TBS being monitored by absorbance at 220 nm and by -ray counting, the peak was marked at 12-13 min of retention time. The fractions around the peak were collected and subjected to another reverse-phase HPLC with a 20-60% linear gradient of acetonitrile. The most 125 I-labeled A was recovered at 36-40% acetonitrile with a retention time at 13 min (Fig. 3B ). The recovered fractions were then analyzed by SDS-PAGE and autoradiography. Before labeling, solubilized A 1-42 gave a single band at less than 7 kDa in SDS-PAGE, the position to which A 1-42 monomers migrated (Fig.   3C ). On the same gel, the 125 I-labeled A was run in parallel and autoradiographed.
A single band was marked at the same position as the CBB-stained cold peptides, indicating that the most 125 I-labeled A 1-42 peptides remained in the monomeric but not the oligomeric form in this condition.
Tissue uptake and distribution of 125 I-labeled A 1-42
Since RAGE is considered to regulate A 1-42 transport and equilibrium between brain and circulation [22, 23] , we then administered radiolabeled A 1-42 and compared its biodistribution among WT, esRAGE Tg and RAGE-null mice. After intravenous bolus injection of 125 I-labeled A , blood, brain, lungs, liver, gallbladder, kidneys, and urine samples were collected at various time points and -ray-counted. The most striking difference was observed in the brain. The brain uptake of radiolabeled A peaked at 30 min in WT mice (0.3% of injected 125 I-labeled A ), but this was blunted both in esRAGE Tg and RAGE-null mice (Fig. 4) . The differences between WT and esRAGE Tg mice and between WT and RAGE-null mice were statistically significant (p<0.0001). The brain uptake at 30 min was not significantly different between esRAGE Tg and RAGE-null mice. The uptake by the lung was also less both in esRAGE Tg and RAGE-null mice at various time points than in WT controls (Fig. 4) . Blood levels of 125 I-labeled A were essentially unchanged during the observation period by 120 min and not significantly different among WT, esRAGE Tg, and RAGE-null mice. We also examined the distribution to metabolic organs, that is, the liver and the kidney, and excretion from them (gallbladder and urine). Injected 125 I-labeled A 1-42 seemed to be excreted into bile and urine in a time-dependent manner, but we could not detect any significant differences in the radioactivities among the three types of animals at every time point tested. However, the early liver uptake of 125 I-labeled A 1-42 (15% of injected 125 I-labeled A in WT mice) was significantly decreased only in RAGE-null mice at 5 min and was significantly increased in esRAGE Tg mice at 15 min after the injection (Fig. 4) . In the kidney, 38% of injected 125 I-labeled A was detected in WT mice at 5 min, and lower radioactivities were noted both in RAGE-null and esRAGE Tg mice at 15 and 30 min, respectively (Fig. 4) .
Radiolabeled A 1-42 distribution in various brain regions
We then conducted autoradiographic analysis of the brain to compare regional distribution of radiolabeled A 1-42 among WT, esRAGE Tg, and RAGE-null mice. The brain was removed 30 min after intravenous injection of 125 I-labeled A , the time point when the significant reduction in the brain uptake of 125 I-labeled A 1-42 was observed in esRAGE Tg and RAGE-null mice. The radioactivity was highest at cerebral ventricles in WT mouse brain (Fig 5) . The signals on cerebral ventricle were significantly decreased in RAGE-null and esRAGE Tg mice compared with those of WT controls. The signals on hippocampal region of RAGE-null and esRAGE Tg mice were weaker than those of WT mice. 
Discussion
The present study has confirmed that human A can engage the multi-ligand receptor RAGE and esRAGE with high affinity (Kd at 44.9 nM). This was demonstrated by direct physical association of A and esRAGE (Fig. 1A, B, and C) and by the peptide competitive inhibition (Fig.1B and C) , and by solid-phase reconstitution of a receptor-ligand binding and the competition assay (Fig.1D) . The results are consistent with the previous reports [6, 39] . Human A The previous studies by Mackic et al. [20] and by Deane et al. [23] showed that the transport of circulating A into the brain is dependent on RAGE expressed at BBB. Accordingly we established for the first time a transgenic mouse line that could abundantly produce circulating esRAGE, which would capture A and prevent the amyloid accumulation in the brain. The murine albumin enhancer/promoter employed in the construction of the transgene efficiently directed the synthesis of large amounts of human esRAGE in serum (Fig. 2) . Total soluble forms of mouse RAGE protein were under the detectable level in the circulation of WT control mice (data not shown), although we reported the expression of mouse esRAGE mRNA and protein in various tissues with high sensitivity techniques [41] . This suggests mouse has more predominant membrane-bound RAGE (signaling RAGE) and less soluble form of RAGE. Accordingly, we accounted WT mice to be membrane-bound RAGE expressors (RAGE >> sRAGE/esRAGE) and the esRAGE Tg mice to be esRAGE >> RAGE models. This was supported by immunoblot analysis of brain extracts from WT, RAGE-null and esRAGE Tg mice (Fig. 2D) ; quantitation of band intensities with Image J program revealed that esRAGE/mRAGE ratio was 0.03 in WT and 2.13 in esRAGE Tg mice.
The resultant esRAGE Tg showed a significant reduction in brain uptake of radiolabeled A 1-42 at 30 min, when the transition of A 1-42 from circulation to the brain parenchyma peaked in WT mice, as did RAGE-null mice (Fig. 4) . The results were comparable with a previous report that recombinant soluble RAGE as well as anti-RAGE neutralizing antibody blocked 125 I-A brain capillary uptake and transport across BBB [23] . Since esRAGE and sRAGE have the same ligand binding domains, this study confirmed the earlier findings showing that sRAGE reduced brain A levels [23] . Maximum reduction of cerebral blood flow as well as RAGE-dependent BBB transport of A was observed at 30 min after intravenous injection of A 1-40 [23] . This coincides with the peak levels of A in brain in the current paper, suggesting that a similar hemodynamic mechanism works in the brain receiving either A or A . In the present study, the distribution of radiolabeled A 1-42 into various brain regions was also investigated. This revealed significant reduction of A 1-42 uptake in regions, including ventricles, cerebral cortex, hippocampus, striatum, thalamus, and putamen, in RAGE-null and esRAGE Tg mice compared with those in WT controls (Fig. 5) . Among those regions, ventricles exhibited the highest accumulation of 125 I-A in WT mice and the most decrease in esRAGE Tg and RAGE-null animals ( Fig. 5A and B) . This suggests that there may be abundant or high-affinity RAGE-dependent binding sites for A RAGE-null mice have neither membrane-bound nor esRAGE in the brain, periphery, and endothelial surface to transport A at BBB, whereas esRAGE mice have excessive esRAGE in the circulation but perhaps normal levels of membrane-bound RAGE at BBB to bind A and transport A. One might expect to see a difference between esRAGE Tg and RAGE-null mice in the data shown in Figs. 4 and 5. However, there seems to be no differences between esRAGE Tg and RAGE-null mice in terms of A 1-42 amount detected in the brain. This may be ascribed to the higher concentration (~g/mL) of human esRAGE in circulation far surpassing the physiologic level of mouse RAGE expressed on the surface of endothelial cells in esRAGE Tg mice. In addition, the formation of esRAGE-A complexes in circulation and the prevention of membrane-bound RAGE-A interaction at BBB would allow the efflux mechanism to prevail [23] , thereby promoting A clearance from brain in esRAGE Tg mice. Among the organs tested, the lung of esRAGE Tg and RAGE-null mice also showed a significant decrease in 125 I-labeled A 1-42 uptake (Fig. 4) . The lung is known to abundantly express RAGE [41] and may have been endowed with an enriched RAGE-mediated mechanism for ligand uptake, as is the case for the BBB. On the other hand, 125 I-A 1-42 levels were the same and unchanged in blood during the 120 min in the WT, RAGE-null and esRAGE Tg mice (Fig. 4) . This may be due to sLRP binding of A in plasma [42] .
The present study revealed that uptake of radiolabeled A to CA1 and CA3 hippocampal regions was decreased by high levels of esRAGE in circulation or by RAGE deficiency (Fig. 5B) . The pyramidal cells in the CA1 region are reported to be vulnerable to degeneration, and this has been related to impaired cognitive function in AD [43] . Our previous study revealed that esRAGE immunoreactivity was decreased in the same regions of hippocampus in AD brains as for non-AD brains [31] . We speculate that, in addition to low expression of esRAGE in the hippocampus, low serum esRAGE may become a risk for AD. In effect, Emanuele et al. reported lower plasma soluble RAGE levels in AD compared with those in non-AD patients or controls [44] .
A and RAGE constitute a vicious cycle of the progression in AD. Ligand engagement of RAGE activates the RAGE gene itself via activation of NF-κB, thus forming a positive loop of regulation [45, 46] . A has been shown to belong to the group of ligands that are able to upregulate RAGE expression [47] [48] [49] [50] . Moreover, A can induce another cascade of post-RAGE signaling; (1) an intracellular calcium mobilization activates nuclear factor activated T cells 1 (NFAT1) to upregulate beta-site APP-cleaving enzyme (BACE) expression, resulting in -secretase-driven A generation [51] , (2) cytokine secretion and proinflammatory reactions [52] , (3) migration of inflammatory cells across BBB [24] . We hypothesize that esRAGE can sequester A for systemic clearance and antagonize A binding to cell surface RAGE, blocking the amplification loop for more RAGE and A 1-42 generation on one hand, and inhibiting RAGE-mediated transport of A into the brain on the other, thereby preventing amyloid aggregation within the brain and subsequent neuronal death.
In conclusion, evidence obtained in the present study suggests a therapeutic potential of esRAGE against AD. In addition, circulating soluble RAGE, including esRAGE, should be a useful biomarker to predict susceptibility/resistance to AD.
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Figure 4
Tissue distribution of radiolabeled A 
